Granted Patent
B2
US 12,324,856 · App. 17/197,204 · Granted Jun 10, 2025
Oral drug dosage form comprising drug in the form of nanoparticles
Assignee:
Triastek, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.
Claims (24)
1. A tablet comprising:
i) a first substrate layer, a second substrate layer, and a third substrate layer, wherein each substrate layer comprises a substrate;
ii) a first nanoparticle layer comprising nanoparticles consisting of a first drug; and
iii) a second nanoparticle layer comprising nanoparticles consisting of a second drug;
wherein the tablet has a multi-layered structure from top to bottom: the first substrate layer, the first nanoparticle layer, the second substrate layer, the second nanoparticle layer, and the third substrate layer; and
wherein the first drug and the second drug are capable of being continuously released from a lateral side of the tablet.
2. The tablet of claim 1 , wherein the first drug and the second drug are different.
3. The tablet of claim 1 , wherein the first drug and the second drug are the same.
4. The tablet of claim 1 , wherein the substrate of each substrate layer is erodible.
5. The tablet of claim 1 , wherein the substrate thickness is different among each substrate layer.
6. The tablet of claim 1 , wherein the substrate thickness is the same among each substrate layer.
7. The tablet of claim 1 , wherein the substrate of each substrate layer comprises a drug embedded therein.
8. The tablet of claim 7 , wherein the drug embedded within the substrate of each substrate layer is different.
9. The tablet of claim 7 , wherein the drug embedded within the substrate of each substrate layer is the same.
10. The tablet of claim 1 , wherein the size of the nanoparticles of the first drug and the second drug is from about 1 nm to about 900 nm.
11. The tablet of claim 10 , wherein the size of the nanoparticles of the first drug and the second drug is from about 100 nm to about 500 nm.
12. The tablet of claim 11 , wherein the size of the nanoparticles of the first drug and the second drug is from about 100 nm to about 200 nm.
13. The tablet of claim 1 , wherein the tablet is produced by three-dimensional (3D) printing.
14. The tablet of claim 1 , wherein the nanoparticles of the first drug and the second drug have the same size.
15. The tablet of claim 1 , wherein the nanoparticles of the first drug and the second drug have different sizes.
16. The tablet of claim 1 , wherein the substrate of each substrate layer is a thermoplastic material.
17. The tablet of claim 16 , wherein the substrate of each substrate layer is independently selected from the group consisting of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57/30/13, polyvinylpyrrolidone-co-vinyl-acetate, polyvinylpyrrolidone-polyvinyl acetate copolymer (PVP-VA) 60/40, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA or PV-OH), poly(ethylene glycol) (PEG), hydroxypropyl methylcellulose or hypromellose (HMPC), hydroxypropyl methylcellulose acetate succinate or hypromellose acetate succinate (HPMCAS), carbomer, hydroxyl propyl cellulose (HPC), Poloxamer, Sucrose, Glucose, and a combination thereof.
18. The tablet of claim 1 , wherein the first nanoparticle layer and the second nanoparticle layer are exposed on the lateral side of the tablet.
19. The tablet of claim 1 , wherein the tablet further comprises a coating.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 11, 2021
From: LI, XIAOLING
To: TRIASTEK, INC.
Reel/Frame 055561/0485 →
Continuity (7)
Provisional Application
62313092
· Mar 24, 2016
Provisional Application
62296087
· Feb 17, 2016
Provisional Application
62170645
· Jun 3, 2015
References Cited (244)
US 3823816A
· Controulis et al.
· 1974
[cited by applicant]
US 4735804A
· Caldwell et al.
· 1988
[cited by applicant]
US 5198229A
· Wong
· 1993
[cited by applicant]
US 5204055A
· Sachs
· 1993
[cited by applicant]
US 5260009A
· Penn
· 1993
[cited by applicant]
US 5340656A
· Sachs
· 1994
[cited by applicant]
US 5342624A
· Mcneill
· 1994
[cited by applicant]
US 5387380A
· Cima
· 1995
[cited by applicant]
US 5490962A
· Cima
· 1996
[cited by applicant]
US 5503785A
· Crump
· 1996
[cited by applicant]
US 5518690A
· Masahashi
· 1996
[cited by applicant]
US 5543155A
· Fekete
· 1996
[cited by applicant]
US 5633021A
· Brown
· 1997
[cited by applicant]
US 5869170A
· Cima
· 1999
[cited by applicant]
US 6264985B1
· Cremer
· 2001
[cited by applicant]
US 6280771B1
· Monkhouse
· 2001
[cited by applicant]
US 6294200B1
· Conte et al.
· 2001
[cited by applicant]
US 6471992B1
· Yoo
· 2002
[cited by applicant]
US 6514518B2
· Monkhouse
· 2003
[cited by applicant]
US 6530958B1
· Cima
· 2003
[cited by applicant]
US 6582726B1
· Geysen
· 2003
[cited by applicant]
US 6685962B2
· Friedman
· 2004
[cited by applicant]
US 6890547B1
· Takada et al.
· 2005
[cited by applicant]
US 7163693B1
· Clarke
· 2007
[cited by applicant]
US 7276252B2
· Payumno
· 2007
[cited by applicant]
US 7300668B2
· Pryce Lewis
· 2007
[cited by applicant]
US 7314640B2
· Sriwongjanya
· 2008
[cited by applicant]
US 7820201B2
· Pryce Lewis
· 2010
[cited by applicant]
US 7875290B2
· Payumo
· 2011
[cited by applicant]
US 7931914B2
· Pryce Lewis
· 2011
[cited by applicant]
US 8088415B2
· Wang
· 2012
[cited by applicant]
US 8465777B2
· Wang
· 2013
[cited by applicant]
US 8673352B2
· Sowden
· 2014
[cited by applicant]
US 8758658B2
· Pryce Lewis
· 2014
[cited by applicant]
US 8828411B2
· Yoo
· 2014
[cited by applicant]
US 9114072B2
· Yoo
· 2015
[cited by applicant]
US 9314429B2
· Jacob
· 2016
[cited by applicant]
US 9339489B2
· Jacob
· 2016
[cited by applicant]
US 20010051185A1
· Faour
· 2001
[cited by applicant]
US 20020106412A1
· Rowe
· 2002
[cited by applicant]
US 20030147952A1
· Lim
· 2003
[cited by applicant]
US 20050249798A1
· Mohammad
· 2005
[cited by applicant]
US 20060099257A1
· Langridge et al.
· 2006
[cited by applicant]
US 20080311191A1
· Nangia et al.
· 2008
[cited by applicant]
US 20090148514A1
· Matthews
· 2009
[cited by applicant]
US 20090317465A1
· Peppas
· 2009
[cited by examiner]
US 20100003332A1
· Bae
· 2010
[cited by examiner]
US 20100226855A1
· Nangia
· 2010
[cited by applicant]
US 20100233253A1
· Kavimandan
· 2010
[cited by examiner]
US 20110111022A1
· Kim et al.
· 2011
[cited by applicant]
US 20130149379A1
· Berner
· 2013
[cited by applicant]
US 20130193621A1
· Daya et al.
· 2013
[cited by applicant]
US 20130344149A1
· Stefan
· 2013
[cited by applicant]
US 20180214383A1
· Sun et al.
· 2018
[cited by applicant]
US 20190209468A1
· Deng
· 2019
[cited by applicant]
US 20210078244A1
· Deng et al.
· 2021
[cited by applicant]
US 20210196638A1
· Deng et al.
· 2021
[cited by applicant]
US 20220212404A1
· Liu et al.
· 2022
[cited by applicant]
US 20230390193A1
· Deng
· 2023
[cited by applicant]
US 20230398066A1
· Deng et al.
· 2023
[cited by applicant]
US 20240041779A1
· Deng
· 2024
[cited by applicant]
US 20240180840A1
· Cao
· 2024
[cited by applicant]
US 20240316864A1
· Deng
· 2024
[cited by applicant]
US 20240342094A1
· Li
· 2024
[cited by applicant]
US 20240408023A1
· Cheng
· 2024
[cited by applicant]
AU 782141B2
· 2005
[cited by examiner]
CN 103948557A
· 2004
[cited by applicant]
CN 1216597C
· 2005
[cited by applicant]
CN 101370483A
· 2009
[cited by applicant]
CN 1620284B
· 2010
[cited by applicant]
CN 105687153A
· 2016
[cited by applicant]
CN 205343831U
· 2016
[cited by applicant]
CN 106491551A
· 2017
[cited by applicant]
CN 106535878A
· 2017
[cited by applicant]
CN 107019676A
· 2017
[cited by applicant]
CN 108215153A
· 2018
[cited by applicant]
CN 108215154A
· 2018
[cited by applicant]
CN 207669820U
· 2018
[cited by applicant]
CN 207901677U
· 2018
[cited by applicant]
CN 105690762A
· 2019
[cited by applicant]
CN 110787145A
· 2020
[cited by applicant]
CN 111249257A
· 2020
[cited by applicant]
CN 109432039B
· 2021
[cited by applicant]
EP 0631775A1
· 1995
[cited by applicant]
EP 1112739A1
· 2001
[cited by applicant]
EP 3302442A1
· 2018
[cited by applicant]
EP 3626439A1
· 2020
[cited by applicant]
GB 436236A
· 1935
[cited by applicant]
JP H09221416A
· 1997
[cited by applicant]
JP 2010523554A
· 2010
[cited by applicant]
JP 2020506918A
· 2020
[cited by applicant]
JP 2020507556A
· 2020
[cited by applicant]
KR 102078805B1
· 2020
[cited by applicant]
WO 199009168A1
· 1990
[cited by applicant]
WO 199213521A1
· 1992
[cited by applicant]
WO 199836738A1
· 1998
[cited by applicant]
WO 199836739A1
· 1998
[cited by applicant]
WO 2000015199A1
· 2000
[cited by applicant]
WO 200038650A1
· 2000
[cited by applicant]
WO 200105406A1
· 2001
[cited by applicant]
WO 200137812A2
· 2001
[cited by applicant]
WO 200137813A2
· 2001
[cited by applicant]
WO 200187272A2
· 2001
[cited by applicant]
WO 200197783A1
· 2001
[cited by applicant]
WO 2003037244A2
· 2003
[cited by applicant]
WO 2003037607A1
· 2003
[cited by applicant]
WO 2003041690A2
· 2003
[cited by applicant]
WO 2003092633A2
· 2003
[cited by applicant]
WO 2004112755A1
· 2004
[cited by applicant]
WO 2005027878A1
· 2005
[cited by applicant]
WO 2006058247A2
· 2006
[cited by applicant]
WO 2007078290A1
· 2007
[cited by applicant]
WO 2008122966A2
· 2008
[cited by applicant]
WO 2009050189A2
· 2009
[cited by applicant]
WO 2009084040A1
· 2009
[cited by applicant]
WO 2009101658A1
· 2009
[cited by applicant]
WO 2009144558A1
· 2009
[cited by applicant]
WO 2014143935A1
· 2014
[cited by applicant]
WO 2014144512A1
· 2014
[cited by applicant]
WO 2014144661A1
· 2014
[cited by applicant]
WO 2014197999A1
· 2014
[cited by applicant]
WO 2015077262A1
· 2015
[cited by applicant]
WO 2015095230A1
· 2015
[cited by applicant]
WO 2015136377A2
· 2015
[cited by applicant]
WO 2015187746A1
· 2015
[cited by applicant]
WO 2016025762A1
· 2016
[cited by applicant]
WO 2016075497A1
· 2016
[cited by applicant]
WO 2016192680A1
· 2016
[cited by applicant]
WO 2017152974A1
· 2017
[cited by applicant]
WO 2017153846A2
· 2017
[cited by applicant]
WO 2017193099A1
· 2017
[cited by applicant]
WO 2018137686A1
· 2018
[cited by applicant]
WO 2018210183A1
· 2018
[cited by applicant]
WO 2019025869A1
· 2019
[cited by applicant]
WO 2019137199A1
· 2019
[cited by applicant]
WO 2019137200A1
· 2019
[cited by applicant]
WO 2019137333A1
· 2019
[cited by applicant]
WO 2019224058A1
· 2019
[cited by applicant]
WO 2021031824A1
· 2021
[cited by applicant]
WO 2021042865A1
· 2021
[cited by applicant]
WO 2021164660A1
· 2021
[cited by applicant]
WO 2022007570A1
· 2022
[cited by applicant]
WO 2022089631A1
· 2022
[cited by applicant]
WO 2022121927A1
· 2022
[cited by applicant]
WO 2022193922A2
· 2022
[cited by applicant]
WO 2024083145A1
· 2024
[cited by applicant]
WO 2024199448A1
· 2024
[cited by applicant]
Anonymous (Aug. 1997). “Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms,” Center for Drug Evaluation and Research, U.S. Food & Drug Administration. FDA-1997-D-0187, 17 pages.
[cited by applicant]
Brooke, D. et al. (Feb. 1977). “Zero-Order Drug Delivery System: Theory and Preliminary Testing,” J. Pharm Scl. 66(2):159-162.
[cited by applicant]
International Search Report, malled Aug. 29, 2016 for PCT Application No. PCT/CN2016/084838, filed Jun. 3, 2016, 4 pages.
[cited by applicant]
Gibson, I. et al. (2015). “Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing,” 2nd ed. Johnson Matthey Technol. Rev. 59(3):193-198.
[cited by applicant]
Goole, J. et al. (Feb. 2016, e-pub. Jan. 3, 2016). “3D printing in Pharmaceutics: A New Tool for Designing Customized Drug Delivery Systems,” Int. J. Pharm. 499(1-2):376-394.
[cited by applicant]
Goyanes, A. et al. (2015). “3D Printing: Engineering Novel Oral Devices With Unique Design and Drug Release Characteristics,” Molecular Pharmaceutics 12(11):3783-4174, 24 pages.
[cited by applicant]
International Preliminary Report on Patentability issued Jul. 30, 2019, for PCT Application No. PCT/CN2018/074146, filed Jan. 25, 2018, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability, issued Dec. 5, 2017 for PCT Application No. PCT/CN2016/084838, filed Jun. 3, 2016, 5 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Apr. 26, 2018, for PCT Application No. PCT/CN2018/074146, filed Jan. 25, 2018, 9 pages.
[cited by applicant]
Katstra, W.E. et al. (Jun. 2001). Fabrication of Complex Oral Delivery Forms by Three Dimensional Printing™, Dissertation in Materials Science and Engineering, Massachusetts Institute of Technology.
[cited by applicant]
Katstra, W.E. et al. (May 3, 2000). “Oral Dosage Forms Fabricated by Three Dimensional Printing,” J. Control Release 66:1-9.
[cited by applicant]
Khaled, S.A. et al. (2015). “3D Printing of Five-in-One Dose Combination Polypill With Defined Immediate and Sustained Release Profiles,” School of Pharmacy, The University of Nottingham 217:308-314, 21 pages.
[cited by applicant]
Khaled, S.A. et al. (Oct. 30, 2015, e-pub. Jul. 30, 2015). “3D Printing of Tablets Containing Multiple Drugs With Defined Release Profiles,” Int. J. Pharm 494(2):643-650.
[cited by applicant]
Lipper, R.A. et al. (Feb. 1977). “Analysis of Theoretical Behavior of a Proposed Zero-Order Drug Delivery System,” J. Pharm Sci. 66(2):163-164.
[cited by applicant]
Melchels, F.P.W. et al. (2010). “A Review on Stereolithography and Its Application in Biomedical Engineering,” Biomaterials 31:6121-6130, 22 pages.
[cited by applicant]
Rowe C.W. et al. (May 3, 2000). “Multimechanism oral Dosage Forms Fabricated by Three Dimensional PrintingTM” Journal of Controlled Release 66(1):11-17.
[cited by applicant]
Srikonda, S. et al. (2006). “Osmotic Controlled Drug Delivery Systems,” Chapter 7 in Design of Controlled Release Drug Delivery Systems, pp. 203-230.
[cited by applicant]
U.S. Appl. No. 16/481,036, filed Jul. 25, 2019, for Cheng et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 16/614,301, filed Nov. 15, 2019, for Cheng et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
Written Opinion of the International Searching Authority, mailed Aug. 29, 2016 for PCT Application No. PCT/CN2016/084838, filed Jun. 3, 2016, 4 pages.
[cited by applicant]
Abdul, S. et al. (2004). “A Flexible Technology for Modified Release of Drugs: Multi-Layered Tablets,” Journal of Controlled Release 97:393-405.
[cited by applicant]
Hatton, G.B. et al. (2015, e-pub Feb. 24, 2015). “Animal Farm: Considerations in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans,” J Pharm Sci., 30 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jan. 30, 2022, for PCT Application No. PCT/CN2021/127852, filed Nov. 1, 2021, 15 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Mar. 9, 2022, for PCT Application No. PCT/CN2021/136353, filed Dec. 8, 2021, 14 pages.
[cited by applicant]
Meyer, D.M. et al. (2010). “Anti-Inflammatory Activity and Neutrophil Reductions Mediated by the JAK1/JAK3 Inhibitor, CP-690,550, in Rat Adjuvant-Induced Arthritis,” J. Inflammation 7:41, 12 pages.
[cited by applicant]
Rawlings, J.S. et al. (2004). “The JAK/STAT Signaling Pathway,” J. Cell Sci. 117(8):1281-1283.
[cited by applicant]
Schwartz, L. et al. (Jan. 1, 2017). “The Warburg Effect and the Hallmarks of Cancer,” Nat Rev Drug Discov. 17(2):164-170, 26 pages.
[cited by applicant]
Shende, P. et al. (2012). “Multi-Layer Tablet: Current Scenario and Recent Advances,” International Journal of Drug Delivery 4:418-426.
[cited by applicant]
Thakral, S. et al. (2013). “Eudragit®: A Technology Evaluation,” Expert Opin. Drug Deliv. 10(1):131-149.
[cited by applicant]
Yoshida, T. et al. (Nov. 2013). “pH- and Ion-Sensitive Polymers For Drug Delivery,” Expert Opinion Drug Delivery 10(11):1497-1513, 28 pages.
[cited by applicant]
Alhnan, M.A. et al. (Aug. 2016, e-published on May 18, 2016). “Emergence of 3D Printed Dosage Forms: Opportunities and Challenges,” Pharm. Res. 33(8):1817-1832, 16 pages.
[cited by applicant]
Cole, G. (1995). Pharmaceutical Coating Technology, Taylor & Francis Publishers, 574 pages.
[cited by applicant]
Ross, A.C. et al. (Feb. 18, 2000). “Chronopharmaceutical Drug Delivery from a Pulsatile Capsule Device Based on Programmable Erosion,” Journal of Pharmacy and Pharmacology 52(8):903-909.
[cited by applicant]
U.S. Appl. No. 18/034,004, filed Apr. 26, 2023, for Deng et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/256,035, filed Jun. 5, 2023, for Deng et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/550,432, filed Sep. 13, 2023, for Cao et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
Kempin, W. et al. (2018, e-pub. Apr. 20, 2018). “Immediate Release 3D-Printed Tablets Produced Via Fused Deposition Modeling of a Thermo-Sensitive Drug,” Pharm. Res. 35:124, 12 pages.
[cited by applicant]
U.S. Appl. No. 18/732,210, filed Jun. 3, 2024, for Cao et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/740,160, filed Jun. 11, 2024, for Xiaoling Li. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/810,262, filed Aug. 20, 2024, for Cheng et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/926,252, filed Oct. 24, 2024, for Wang et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
U.S. Appl. No. 18/927,582, filed Oct. 25, 2024, for Li et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
Khaled, S.A. et al. (Jan. 30, 2014). “Desktop 3D Printing of Controlled Release Pharmaceutical Bilayer Tablets,” International Journal of Pharmaceutics 461(1-2):105-111, 17 pages.
[cited by applicant]
Klausner, E.A. et al. (Jun. 24, 2003). “Expandable Gastroretentive Dosage Forms,” Journal of Controlled Release 90(2):143-162.
[cited by applicant]
Kushner, J. et al. (2020, e-pub. Dec. 19, 2019). “Development and Validation of a Level A in-vitro in-vivo Correlation for Tofacitinib Modified-Release Tablets Using Extrudable Core System Osmotic Delivery Technology,” …
[cited by applicant]